UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
MAP
PHARMACEUTICALS, INC.
(Exact
Name of Registrant as Specified in its Charter)
|
|
|
|
|
Delaware
|
|
001-33719
|
|
20-0507047
|
(State
or Other Jurisdiction
of
Incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
|
|
|
2400
Bayshore Parkway, Suite 200,
Mountain
View, CA
|
|
94043
|
(Address
of Principal Executive Offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (650) 386-3100
(Former
Name or Former Address, if Changed Since Last Report.)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General
Instruction A.2. below):
¨
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Item 2.02
|
Results
of Operations and Financial
Condition
|
On
November 5, 2010, MAP Pharmaceuticals, Inc. (“MAP”) issued a press release
announcing its financial results for its third quarter ended September 30, 2010.
A copy of this press release is furnished as Exhibit 99.1 to this Current Report
on Form 8-K.
The
information in this Item 2.02 of this Current Report on Form 8-K and the
information contained in Exhibit 99.1 shall not be deemed “filed” for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended (the
“Exchange Act”), or otherwise subject to the liabilities of that Section. The
information in this Item 2.02 of this Current Report on Form 8-K and
the press release referenced herein is not incorporated by reference into any
filings of MAP under the Securities Act of 1933, as amended, or the Exchange
Act, whether made before or after the date of this Current Report on Form 8-K,
regardless of any general incorporation language in the filing, unless
explicitly incorporated by specific reference into such filing.
Item 9.01
|
Financial
Statements and Exhibits
|
|
|
|
Exhibit No.
|
|
Description
|
|
|
99.1
|
|
Press
Release of MAP Pharmaceuticals, Inc., dated November 5,
2010
|
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
Date: November
5, 2010
|
MAP
PHARMACEUTICALS, INC.
|
|
|
|
|
|
By:
|
|
/s/
Charlene A.
Friedman
|
|
|
Name:
|
|
Charlene
A. Friedman
|
|
|
Title:
|
|
Vice
President, General Counsel and
Secretary
|
INDEX
TO EXHIBITS FILED WITH
THE
CURRENT REPORT ON FORM 8-K DATED NOVEMBER 5, 2010
|
|
|
Exhibit
|
|
Description
|
|
|
99.1
|
|
Press
Release of MAP Pharmaceuticals, Inc., dated November 5,
2010.
|